Valuation : AtaiBeckley

Market Cap 2.73B 2.35B 2.22B 2.02B 3.78B 260B 3.8B 26.41B 10.16B 132B 10.24B 10.01B 419B P/E 2026 *
-19.2x
P/E 2027 * -17x
Enterprise Value 2.59B 2.23B 2.11B 1.91B 3.59B 247B 3.61B 25.06B 9.64B 126B 9.71B 9.5B 397B EV / Sales 2026 *
845x
EV / Sales 2027 * 4,296x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+0.82%
1 week-0.54%
Current month+0.14%
1 month+1.94%
3 months+93.42%
6 months+81.03%
Current year+79.71%
1 week 7.23
Extreme 7.23
7.4
1 month 7.22
Extreme 7.22
7.45
Current year 3.26
Extreme 3.265
7.45
1 year 3.26
Extreme 3.265
7.45
3 years 1.02
Extreme 1.025
7.45
5 years 1.02
Extreme 1.025
17.81
10 years 1.02
Extreme 1.025
22.91
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26 Exercice

Director

300,000 0.0815%
25/06/26 Exercice

Chief Technology Officer

127,737 0.0347%
04/06/26 Free

Director

121,968 0.0331%

Financials

2026 *2027 *
Net sales 3.06M 2.64M 2.5M 2.26M 4.24M 292M 4.27M 29.65M 11.4M 149M 11.49M 11.24M 470M 600K 517K 489K 444K 832K 57.32M 837K 5.81M 2.24M 29.16M 2.25M 2.2M 92.15M
Net income -144M -124M -117M -106M -200M -13.75B -201M -1.39B -536M -7B -541M -529M -22.1B -166M -143M -136M -123M -231M -15.88B -232M -1.61B -619M -8.08B -624M -610M -25.52B
Net Debt -139M -120M -114M -103M -193M -13.3B -194M -1.35B -519M -6.77B -523M -511M -21.38B -148M -128M -121M -110M -206M -14.18B -207M -1.44B -553M -7.21B -557M -545M -22.79B
Logo AtaiBeckley
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
Employees
99
Sector
-
Date Price Change Volume
10/09/26 $7.350 +0.82% 9,587,449
09/09/26 $7.290 +0.14% 14,857,224
08/09/26 $7.280 -1.49% 119,760,747
04/09/26 $7.390 +0.68% 10,313,859
03/09/26 $7.340 -0.14% 17,481,660
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
7.350USD
Average target price
8.117USD
Spread / Average Target
+10.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATAI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!